Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Amgen

Jailed Dutch-Chinese scientist 'forgotten' by his country and company

Dr Zhang Mingqiang is in cell number 204 of Shanghai’s notorious Qingpu prison – sentenced to six years for spying. He worked for US pharmaceutical giant Amgen in charge of research and development at their Asian operations. Caught in the crossfire between Beijing, the US and the EU, Zhang and…

Radio France Internationale

A more aggressive FTC is starting to target drug mergers and industry middlemen

Under the leadership of an aggressive opponent of anti-competitive business practices, the Federal Trade Commission is moving against drug companies and industry middlemen as part of the Biden administration’s push for lower drug prices at the pharmacy counter.

Tribune News Service

Stocks Undercut as Little Progress is seen in U.S. Debt Ceiling Talks

What you need to know… The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -0.63%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -1.01%, and the Nasdaq 100 Index ($IU ) (QQQ ) closed up +0.09%. Stock indexes Tuesday settled mixed, with the Dow Jones...

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Monopoly concerns push FTC to sue to block Amgen's more than $26B deal for Horizon

Federal regulators are suing to block biotech drug developer Amgen’s more than $26 billion deal for Horizon Therapeutics

The Independent UK

Stocks Mixed as Debt Ceiling Talks Resume

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is down -0.41%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.70%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.16%. U.S. stocks this morning are mixed, with the Dow...

Barchart

Markets Today: Stocks Slip Ahead of U.S. Debt Ceiling Talks

Morning Markets June E-Mini S&P 500 futures (ESM2 3) this morning are down -0.26%, and June Nasdaq 100 E-Mini futures (NQM2 3) are down -0.21%. U.S. stock index futures this morning are moderately lower as the markets await any new developments on the debt ceiling stalemate. President Biden will meet...

Barchart

The drug company that prospered without creating any drugs

The new drug looked so promising — except for that one warning sign.

Tribune News Service

Read news from The Economist, FT, and more,
with one subscription

How Horizon Therapeutics sold to Amgen for $27.8 billion without ever licensing a drug of its own

Horizon grew large by snapping up cheap drugs from other companies, marketing them to perfection, and jacking up prices.

Fortune

3 High-Quality Stocks to Add to Your Watchlist Now

Despite the bank failures, the Fed will likely keep raising interest rates to bring inflation down. This is expected to keep the stock market under pressure. Amid this backdrop, it could be wise for investors to add high-quality stocks Visa (V), Amgen (AMGN), and Box (BOX) to their watchlist. Keep…

StockNews.com

3 Dow Stocks to Buy More of in March 2023

With the Fed keen on further interest rate hikes this year, the stock market will likely remain under pressure. Amid this backdrop, it could be wise for investors to buy fundamentally strong Dow stocks like Verizon Communications (VZ), Amgen (AMGN), and International Business Machines (IBM). Read more….

StockNews.com

Obesity treatments catch drugmakers’ eyes as sales seen soaring

Three years ago, drugmakers and laboratories around the world responded to the pandemic with Covid-19 vaccines. Now that the urgency has faded, they’re collectively turning attention to an older pandemic: obesity.

Tribune News Service

Amgen to buy Horizon Therapeutics in $26.4B deal

Horizon Therapeutics, whose U.S. headquarters is in Deerfield, is a biopharmaceutical company that focuses on treatments for rare, autoimmune diseases.

Chicago Sun-Times

Amgen to buy Horizon Therapeutics in $26.4B deal

Amgen will acquire Horizon Therapeutics, a biopharmaceutical company that focuses on treatments for rare, autoimmune diseases, for about $26.4 billion

The Independent UK

This US Representative Just Bought Shares Of Airbnb And These 2 Dividend-Paying Stocks

Congressman Josh Gottheimer (D-NJ) has made over 1,200 trades in the past three years, with his top two traded stocks being Microsoft (NASDAQ: MSFT) and Apple (NASDAQ: AAPL), reported b

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Amgen Unusual Options Activity

Someone with a lot of money to spend has taken a bullish stance on Amgen (NASDAQ:AMGN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Musk Reportedly Suspends Twitter Work On Crypto Wallet, Boeing's Jeppesen Hit By Potential Ransomware Attack, Lyft Cuts Workforce: Top Stories Friday, Nov. 04

Reuters

Benzinga

Looking At Amgen's Recent Unusual Options Activity

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022

Upgrades

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

1 Biotech Stock to Double Down on in Q4

Leading drug maker Amgen (AMGN) delivered impressive second-quarter results. The company is well-positioned for solid long-term growth, driven by its diversified and growing product portfolio, rising demand from a rapidly aging population, and continued advancements in science and technology. Given its high profitability, attractive dividends, and bright growth prospects, we…

StockNews.com

Amgen is Our Growth Stock of the Week…

Biotech stocks are outperforming due to attractive valuations and strong catalysts. Amgen (AMGN) is one of the top stocks in the space due to its strong product portfolio, pipeline, and impressive management team. Read on to find out why it's our stock of the week.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022

Upgrades

Benzinga

Amgen Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Amgen. Looking at options history for Amgen (NASDAQ:AMGN) we detected 22 strange trades.

Benzinga

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

Amgen (NASDAQ:AMGN) announced top-line results from the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS (sotorasib) in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), the study met primary endpoint. Amgen shares traded in a range of $238.29 to $240.31 on day volume of 2.43 million shares, closed regular…

StockNews.com

2 Biotech Stocks to Buy and Hold for the Long Term

Intensive innovation, breakthrough developments, and growing investments should help the biotech industry witness solid growth over the next decade. And given the sector’s reputation as a safe haven amid economic turmoil, it could be wise for investors to buy and hold fundamentally solid biotech stocks Amgen (AMGN) and AstraZeneca (AZN)…

Benzinga

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Merck's (NYSE:MRK) lead asset MK-2060 for the reduction in risk of major thrombotic cardiovascular events in patients with end-stage renal disease (ESRD). Merck shares traded in a range of $89.72 to $90.97 on day volume of 5.2…

1 … 4 5 6 7

People

Mangeet Kaur BounsMangeet

Jaimini DesaiJaimini Desai

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.